Characterization of the tumor immune microenvironment (TME) in early stage HR-positive HER2-positive breast cancer

被引：0
|
作者：
Fenn, Kathleen M. [1 ]
Marks, Douglas K. [2 ]
Vanguri, Rami [1 ]
Boboila, Shuobo [1 ]
Guo, Hua [1 ]
Hibshoosh, Hanina [1 ]
Kalinsky, Kevin [1 ]
Connolly, Eileen [1 ]
机构：
[1] Columbia Univ, Irving Med Ctr, New York, NY USA
[2] NYU, New York, NY USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P6-10-25
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-10-25
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Differences in tumor microenvironment between HER2-positive and HER2-negative breast cancer.
    Gong, Chang
    Lin, Qun
    Cen, Yinghuan
    Fang, Xiaolin
    Shi, Yu
    Chen, Letian
    Luo, Qing
    Duan, Zhuxi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] Efficacy and Safety of Anti-HER2 Targeted Therapy for Metastatic HR-Positive and HER2-Positive Breast Cancer: A Bayesian Network Meta-Analysis
    Wu, Xian-Meng
    Qian, Yong-Kang
    Chen, Hua-Ling
    Hu, Chen-Hua
    Chen, Bing-Wei
    CURRENT ONCOLOGY, 2023, 30 (09) : 8444 - 8463
  • [23] Patterns in use and tolerance of adjuvant neratinib in patients with hormone receptor (HR)-positive, HER2-positive early-stage breast cancer
    Blanter, Julia
    Baldwin, Elena
    Patel, Rima
    Sheng, Tianxiang
    Tiersten, Amy
    BREAST CANCER RESEARCH AND TREATMENT, 2024, : 461 - 466
  • [24] Complete response to pyrotinib combined with letrozole as first-line treatment of HER2-positive/HR-positive breast cancer: a case report
    Xie, Ning
    Liu, Liping
    Tian, Can
    Hu, Zheyu
    Ouyang, Quchang
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (16)
  • [25] HER2-positive breast cancer
    Loibl, Sibylle
    Gianni, Luca
    LANCET, 2017, 389 (10087): : 2415 - 2429
  • [26] Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer
    Hong, Joohyun
    Park, Yeon Hee
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [27] Exemestane plus entinostat in HR-positive/HER2-negative breast cancer?
    Lichert, Frank
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (01) : 18 - 18
  • [28] Systemic Therapy of HR-positive, HER2-negative metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (03) : 257 - 257
  • [29] A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer.
    Cascetta, Krystal Pauline
    Poulikakos, Poulikos
    Shapiro, Charles L.
    Bhardwaj, Aarti Sonia
    Fasano, Julie
    Irie, Hanna
    Klein, Paula
    Goel, Anupama
    Kalinsky, Kevin
    Adams, Sylvia
    Andreopoulou, Eleni
    Jaffer, Shabnam
    Ru, Meng
    Tiersten, Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Accelerated Partial Breast Irradiation for HER2-Positive Early-Stage Breast Cancer
    O'Brien D.R.
    Boe L.
    Montagna G.
    Mueller B.
    Chino F.
    Cuaron J.
    Choi J.I.
    Xu A.
    Bernstein M.
    McCormick B.
    Powell S.
    Khan A.J.
    Braunstein L.Z.
    International Journal of Radiation Oncology Biology Physics, 2024, 118 (02): : 468 - 473
12345